SK281964B6 - Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm - Google Patents
Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm Download PDFInfo
- Publication number
- SK281964B6 SK281964B6 SK255-96A SK25596A SK281964B6 SK 281964 B6 SK281964 B6 SK 281964B6 SK 25596 A SK25596 A SK 25596A SK 281964 B6 SK281964 B6 SK 281964B6
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- bmap
- antibody
- monoclonal antibody
- cell
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 22
- 239000012634 fragment Substances 0.000 title abstract description 4
- 210000004027 cell Anatomy 0.000 title description 124
- 230000006907 apoptotic process Effects 0.000 title description 8
- 239000000427 antigen Substances 0.000 claims abstract description 29
- 102000036639 antigens Human genes 0.000 claims abstract description 29
- 108091007433 antigens Proteins 0.000 claims abstract description 29
- 230000031957 myeloid cell apoptotic process Effects 0.000 claims abstract description 18
- 210000000066 myeloid cell Anatomy 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 210000002798 bone marrow cell Anatomy 0.000 description 24
- 210000002536 stromal cell Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 238000010185 immunofluorescence analysis Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 210000004989 spleen cell Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 210000003887 myelocyte Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 230000003394 haemopoietic effect Effects 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000001167 myeloblast Anatomy 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- -1 β-glucouronidase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP05242110 | 1993-09-03 | ||
| PCT/JP1994/001453 WO1995006748A1 (fr) | 1993-09-03 | 1994-09-02 | Anticorps monoclonal permettant d'induire une apoptose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK25596A3 SK25596A3 (en) | 1996-10-02 |
| SK281964B6 true SK281964B6 (sk) | 2001-09-11 |
Family
ID=17084452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK255-96A SK281964B6 (sk) | 1993-09-03 | 1994-09-02 | Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US5840344A (hu) |
| EP (1) | EP0721015B1 (hu) |
| KR (1) | KR100241863B1 (hu) |
| CN (1) | CN1046314C (hu) |
| AT (1) | ATE280835T1 (hu) |
| AU (1) | AU692466B2 (hu) |
| CA (1) | CA2169950A1 (hu) |
| CZ (1) | CZ294359B6 (hu) |
| DE (1) | DE69434097T2 (hu) |
| FI (1) | FI960567A (hu) |
| HU (1) | HU222989B1 (hu) |
| NO (1) | NO960684D0 (hu) |
| PL (1) | PL181783B1 (hu) |
| RU (1) | RU2202615C2 (hu) |
| SK (1) | SK281964B6 (hu) |
| TW (1) | TW426687B (hu) |
| UA (1) | UA50708C2 (hu) |
| WO (1) | WO1995006748A1 (hu) |
| ZA (1) | ZA946767B (hu) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100241863B1 (ko) * | 1993-09-03 | 2000-03-02 | 나가야마 오사무 | 아포토시스를 야기시키는 모노클론성항체 |
| US6579692B1 (en) | 1996-03-06 | 2003-06-17 | Chugai Seiyaku Kabushiki Kaisha | Method of screening apoptosis inducing substances |
| EP0935001B2 (en) | 1996-07-15 | 2011-08-10 | Chugai Seiyaku Kabushiki Kaisha | Novel vegf-like factors |
| US7531643B2 (en) | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| CA2303072A1 (en) * | 1997-09-11 | 1999-03-18 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| WO2000053634A1 (fr) * | 1999-03-10 | 2000-09-14 | Chugai Seiyaku Kabushiki Kaisha | Fv monocatenaire induisant l'apoptose |
| US20040058393A1 (en) * | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
| RU2408606C2 (ru) | 2000-10-20 | 2011-01-10 | Тугаи Сейяку Кабусики Кайся | Соединение - агонист тро |
| JP4261907B2 (ja) * | 2000-10-20 | 2009-05-13 | 中外製薬株式会社 | 低分子化アゴニスト抗体 |
| US7195771B1 (en) | 2000-11-21 | 2007-03-27 | Kimberly-Clark Worldwide, Inc. | Water-soluble lotions for paper products |
| AU2002361642A1 (en) * | 2001-11-16 | 2003-06-10 | The University Of Tennessee Research Corporation | Recombinant antibody fusion proteins and methods for detection of apoptotic cells |
| WO2004033499A1 (ja) | 2002-10-11 | 2004-04-22 | Chugai Seiyaku Kabushiki Kaisha | 細胞死誘導剤 |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| EP1609803A4 (en) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODY AGAINST CD22 AND ITS USE |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20070281327A1 (en) * | 2003-12-12 | 2007-12-06 | Kiyotaka Nakano | Methods of Screening for Modified Antibodies With Agonistic Activities |
| TW200530266A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Method of reinforcing antibody activity |
| EP1712565A4 (en) * | 2003-12-12 | 2009-03-11 | Chugai Pharmaceutical Co Ltd | AGENTS INDUCING CELL DEATH |
| US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
| EP1927367A4 (en) * | 2005-05-18 | 2009-08-12 | Univ Tokushima | NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY |
| CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| WO2007100892A2 (en) * | 2006-02-28 | 2007-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Trojan horse immunotherapy |
| JPWO2008007755A1 (ja) * | 2006-07-13 | 2009-12-10 | 中外製薬株式会社 | 細胞死誘導剤 |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| EP3227436A4 (en) | 2014-12-05 | 2018-06-20 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| IL259747B (en) | 2015-12-04 | 2022-09-01 | Memorial Sloan Kettering Cancer Center | Antibodies against fcrl5 and methods of their use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100241863B1 (ko) * | 1993-09-03 | 2000-03-02 | 나가야마 오사무 | 아포토시스를 야기시키는 모노클론성항체 |
| US6579692B1 (en) * | 1996-03-06 | 2003-06-17 | Chugai Seiyaku Kabushiki Kaisha | Method of screening apoptosis inducing substances |
| CA2303072A1 (en) * | 1997-09-11 | 1999-03-18 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| WO2000053634A1 (fr) * | 1999-03-10 | 2000-09-14 | Chugai Seiyaku Kabushiki Kaisha | Fv monocatenaire induisant l'apoptose |
-
1994
- 1994-09-02 KR KR1019960700821A patent/KR100241863B1/ko not_active IP Right Cessation
- 1994-09-02 PL PL94313260A patent/PL181783B1/pl not_active IP Right Cessation
- 1994-09-02 CZ CZ1996617A patent/CZ294359B6/cs not_active IP Right Cessation
- 1994-09-02 HU HU9600206A patent/HU222989B1/hu not_active IP Right Cessation
- 1994-09-02 DE DE69434097T patent/DE69434097T2/de not_active Expired - Fee Related
- 1994-09-02 CA CA002169950A patent/CA2169950A1/en not_active Abandoned
- 1994-09-02 EP EP94925618A patent/EP0721015B1/en not_active Expired - Lifetime
- 1994-09-02 ZA ZA946767A patent/ZA946767B/xx unknown
- 1994-09-02 US US08/605,059 patent/US5840344A/en not_active Expired - Lifetime
- 1994-09-02 AT AT94925618T patent/ATE280835T1/de not_active IP Right Cessation
- 1994-09-02 RU RU96107203/13A patent/RU2202615C2/ru not_active IP Right Cessation
- 1994-09-02 CN CN94193260A patent/CN1046314C/zh not_active Expired - Fee Related
- 1994-09-02 SK SK255-96A patent/SK281964B6/sk unknown
- 1994-09-02 AU AU75466/94A patent/AU692466B2/en not_active Ceased
- 1994-09-02 WO PCT/JP1994/001453 patent/WO1995006748A1/ja active IP Right Grant
- 1994-09-02 UA UA96030813A patent/UA50708C2/uk unknown
- 1994-11-19 TW TW083110887A patent/TW426687B/zh not_active IP Right Cessation
-
1996
- 1996-02-07 FI FI960567A patent/FI960567A/fi not_active Application Discontinuation
- 1996-02-21 NO NO960684A patent/NO960684D0/no not_active Application Discontinuation
-
1998
- 1998-09-17 US US09/154,498 patent/US6267959B1/en not_active Expired - Lifetime
-
2000
- 2000-12-15 US US09/736,146 patent/US6759043B2/en not_active Expired - Fee Related
-
2003
- 2003-03-03 US US10/376,628 patent/US20030147894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20010001712A1 (en) | 2001-05-24 |
| RU2202615C2 (ru) | 2003-04-20 |
| WO1995006748A1 (fr) | 1995-03-09 |
| CN1046314C (zh) | 1999-11-10 |
| ATE280835T1 (de) | 2004-11-15 |
| NO960684L (no) | 1996-02-21 |
| SK25596A3 (en) | 1996-10-02 |
| PL313260A1 (en) | 1996-06-24 |
| FI960567A0 (fi) | 1996-02-07 |
| CZ294359B6 (cs) | 2004-12-15 |
| HU222989B1 (hu) | 2004-01-28 |
| US6267959B1 (en) | 2001-07-31 |
| FI960567A (fi) | 1996-02-07 |
| HU9600206D0 (en) | 1996-03-28 |
| HUT74594A (en) | 1997-01-28 |
| DE69434097T2 (de) | 2006-02-02 |
| EP0721015A1 (en) | 1996-07-10 |
| CZ61796A3 (en) | 1996-06-12 |
| US6759043B2 (en) | 2004-07-06 |
| EP0721015A4 (en) | 1999-03-31 |
| US20030147894A1 (en) | 2003-08-07 |
| NO960684D0 (no) | 1996-02-21 |
| UA50708C2 (uk) | 2002-11-15 |
| TW426687B (en) | 2001-03-21 |
| PL181783B1 (pl) | 2001-09-28 |
| DE69434097D1 (de) | 2004-12-02 |
| AU692466B2 (en) | 1998-06-11 |
| ZA946767B (en) | 1995-04-03 |
| EP0721015B1 (en) | 2004-10-27 |
| CA2169950A1 (en) | 1995-03-09 |
| US5840344A (en) | 1998-11-24 |
| AU7546694A (en) | 1995-03-22 |
| CN1130405A (zh) | 1996-09-04 |
| KR100241863B1 (ko) | 2000-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK281964B6 (sk) | Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm | |
| US6579692B1 (en) | Method of screening apoptosis inducing substances | |
| KR100895749B1 (ko) | Ｎｋｇ２ｄ의 조절 | |
| KR20040106585A (ko) | 아포토시스를 유기하는 모노클로날 항체 | |
| IE50420B1 (en) | Monoclonal antibody to human t cells,method for preparing it,therapeutic composition comprising it and diagnostic method using it | |
| US4818689A (en) | Late differentiation antigen associated with helper T lymphocyte function | |
| JP3725653B2 (ja) | アポトーシスを誘起する物質のスクリーニング方法 | |
| JP3984688B2 (ja) | アポトーシスを誘起するモノクローナル抗体を有効成分とする医薬 | |
| SK281965B6 (sk) | Monoklonálna protilátka inhibujúca zachytávanie krvotvorných kmeňových buniek a hybridóm | |
| JP2741483B2 (ja) | アポトーシスを誘起するモノクローナル抗体 | |
| JPS6363556B2 (hu) | ||
| JPH08208697A (ja) | アポトーシスを誘起するモノクローナル抗体を有効成分とする医薬 | |
| JPH07118299A (ja) | 間質細胞表面抗原を認識するモノクローナル抗体 |